ReviewJournal of thrombosis and thrombolysis2016
PCSK9 inhibitors in the prevention of cardiovascular disease.
Review in Journal of thrombosis and thrombolysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Residual inflammatory risk after contemporary lipid lowering therapy.European heart journal. Quality of care & clinical outcomes · 2020Pooled it
- Serum PCSK9 is not independently associated with dyslipidaemia in type 2 diabetes: a paired cross-sectional study.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
- Review
- Population Heterogeneity and Selection of Coronary Artery Disease Polygenic Scores.Journal of personalized medicine · 2024Article
- Exploring Phytochemical Mechanisms in the Prevention of Cholesterol Dysregulation: A Review.Journal of agricultural and food chemistry · 2024Review
- Blocking cholesterol formation and turnover improves cellular and mitochondria function in murine heart microvascular endothelial cells and cardiomyocytes.Frontiers in physiology · 2023Article
- Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.EXCLI journal · 2022Review
- Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis.Journal of clinical medicine · 2021Review
- The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury.The Journal of clinical investigation · 2021Article
- Finding inhibitors for PCSK9 using computational methods.PloS one · 2021Article
- Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.Stem cell research & therapy · 2019Article
- Implementing genome-driven personalized cardiology in clinical practice.Journal of molecular and cellular cardiology · 2018Review
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.Circulation · 2017Observational
- Genetics of Dyslipidemia and Ischemic Heart Disease.Current cardiology reports · 2017Review
- PCSK9 as a therapeutic target for cardiovascular disease.Experimental and therapeutic medicine · 2017Article
- Genes for a 'Wellderly' Life.Trends in molecular medicine · 2016Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with currently available lipid-lowering drugs. Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic strategy to reduce residual cardiovascular disease risk. Binding of PCSK9 to the LDL receptor targets the receptor for lysosomal degradation. The recognition that inhibition of PCSK9 increases LDL receptor activity has led to the development of a number of approaches to directly target PCSK9. Numerous monoclonal antibodies against PCSK9 are currently being evaluated in phase 3 trials, involving various patient categories on different background lipid-lowering therapies. Current evidence shows reductions in LDL-C levels of up to 70 % may be achieved with PCSK9 inhibition, independent of background statin therapy. This review examines the most recent evidence and future prospects for the use of PCSK9 inhibitors in the prevention of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.